Toutes les études
RecrutementConfirmatoire thérapeutique (Phase III)Interventionnel

A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

This research study, called TrustTSC OLE, is investigating a new medication, ganaxolone, for adults who experience seizures due to Tuberous Sclerosis Complex (TSC). This is an important step to understand if ganaxolone can be safely used to help manage seizures in people living with TSC. The study will closely monitor participants' health, including any side effects, to make sure the treatment is safe. It will also track how often seizures occur to see if the medicine helps. By participating, you could help doctors learn more about improving treatment options for TSC-related epilepsy.

En un coup d'œil

Statut
Recrutement
Phase
Confirmatoire thérapeutique (Phase III)
Sponsor
Marinus Pharmaceuticals Inc.
Objectif d'inscription
51
Démarrer
03 Jul 2023

De quoi parle cette étude ?

This study is looking at a new medicine called ganaxolone for people who have epilepsy because of a condition called Tuberous Sclerosis Complex (TSC). TSC can cause many different health problems, and epilepsy (seizures) is a common one. Finding effective and safe ways to control these seizures is very important for improving people's daily lives.

The main goal of this study is to check how safe ganaxolone is. This means doctors will be carefully looking for any side effects the medicine might cause and how serious they are. They will also see if people need to stop taking the medicine or reduce their dose because of these side effects. Your overall health will be checked regularly throughout the study.

The study will also measure how well ganaxolone works at reducing seizures. Doctors will compare how many seizures participants have before starting the medicine with how many they have during the study. This helps them understand if the medicine is actually helping to control the epilepsy. They will also look at how the medicine affects a person's general well-being and quality of life.

Points clés

  • This study is for adults with Tuberous Sclerosis Complex (TSC) who experience epilepsy.
  • It tests a new medicine called ganaxolone.
  • The main goals are to check the medicine's safety and see if it helps reduce seizures.
  • Participation involves regular health checks and recording seizure information.
  • You could gain access to a new treatment and help advance medical knowledge.

Qui peut être éligible ?

This study is particularly for adults who have epilepsy due to Tuberous Sclerosis Complex (TSC).

If you are 18 years old or older and have a diagnosis of TSC that causes epilepsy, you might be able to take part.

Both men and women are welcome to participate. The study team will need to check your medical history to make sure this study is right for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have Tuberous Sclerosis Complex (TSC)?
  3. Does your TSC cause you to have epilepsy (seizures)?
  4. Êtes-vous en mesure d'assister à des rendez-vous réguliers pour des examens de contrôle ?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will be given the medicine ganaxolone. You'll have regular visits with the study team where they will check your health. These checks will include things like measuring your blood pressure and heart rate, taking blood samples for lab tests, and having an electrocardiogram (ECG) to check your heart. Doctors will also check your physical condition and how you are developing.

You will need to keep a record of your seizures. The study will look at how your seizure frequency changes over time, especially during the first year of treatment. There will also be questionnaires to assess your quality of life. The study will last for a long period, with particular focus on the first year of treatment for some measurements.

Risques et avantages potentiels

Taking part in a study like this might offer potential benefits, such as access to a new treatment for your TSC-related epilepsy before it's widely available. It also contributes to scientific knowledge that could help many others in the future. However, there are potential risks, as the medicine may cause side effects, some of which could be serious. You will be closely monitored for any health changes. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (5)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    Allemagne
  • —
    Non vérifié
    Espagne
  • —
    Non vérifié
    Italie
  • —
    Non vérifié
    France
  • —
    Non vérifié
    Belgique

Questions fréquentes

What is ganaxolone?

Ganaxolone is the new medicine being studied to help people with epilepsy caused by Tuberous Sclerosis Complex (TSC).

What is Tuberous Sclerosis Complex (TSC) related epilepsy?

It's when someone has seizures (epilepsy) that are caused by the genetic condition Tuberous Sclerosis Complex.

Combien de temps durera l'étude ?

The study is a long-term one, and some key measurements, like seizure frequency and quality of life, will be closely looked at during the first year.

Will I know if the medicine is working for me?

The study team will monitor your seizure frequency and overall health, and you'll have regular check-ups to discuss your progress.

Que faire si j'ai des effets secondaires ?

The study team will closely watch you for any side effects, and they will be there to help you manage them. Your safety is their top priority.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) T… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.